{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:08:16Z","timestamp":1775646496710,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gen. Psychiatry"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperprolactinaemia is a common antipsychotic (AP)\u2010induced adverse effect, particularly in female patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This meta\u2010analysis examined the efficacy and safety of adjunctive aripiprazole in preventing AP\u2010related hyperprolactinaemia in patients with first\u2010episode schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, PsycINFO, EMBASE, Cochrane Library, WanFang and China Journal Net databases were searched to identify eligible randomised controlled trials (RCTs). Primary outcomes were the reductions of serum prolactin level and prolactin\u2010related symptoms. Data were independently extracted by two reviewers and analysed using RevMan (V.5.3). Weighted\/standardised mean differences (WMDs\/SMDs)\u00b195% CIs were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the five RCTs (n=400), the adjunctive aripiprazole (n=197) and the control groups (n=203) with a mean of 11.2 weeks of treatment duration were compared. The aripiprazole group had a significantly lower endpoint serum prolactin level in all patients (five RCTs, n=385; WMD: \u221250.43\u2009ng\/mL (95%\u2009CI: \u221275.05 to \u221225.81), p&lt;0.00001; I\n                      <jats:sup>2<\/jats:sup>\n                      =99%), female patients (two RCTs, n=186; WMD: \u221222.58\u2009ng\/mL (95%\u2009CI: \u221225.67 to \u221219.49), p&lt;0.00001; I\n                      <jats:sup>2<\/jats:sup>\n                      =0%) and male patients (two RCTs, n=127; WMD: \u221268.80\u2009ng\/mL (95%\u2009CI: \u2212100.11 to \u221237.49), p&lt;0.0001). In the sensitivity analysis for the endpoint serum prolactin level in all patients, the findings remained significant (p&lt;0.00001; I\n                      <jats:sup>2<\/jats:sup>\n                      =96%). The aripiprazole group was superior to the control group in improving negative symptoms as assessed by the Positive and Negative Syndrome Scale (three RCTs, n=213; SMD: \u22120.51 (95% CI: \u22120.79 to \u22120.24), p=0.0002; I\n                      <jats:sup>2<\/jats:sup>\n                      =0%). Adverse effects and discontinuation rates were similar between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adjunctive aripiprazole appears to be associated with reduced AP\u2010induced hyperprolactinaemia and improved prolactin\u2010related symptoms in first\u2010episode schizophrenia. Further studies with large sample sizes are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gpsych-2019-100091","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T13:15:14Z","timestamp":1571318114000},"update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Adjunctive aripiprazole for antipsychotic\u2010related hyperprolactinaemia in patients with first\u2010episode schizophrenia: a meta\u2010analysis"],"prefix":"10.1002","volume":"32","author":[{"given":"Wei","family":"Zheng","sequence":"first","affiliation":[{"name":"The Affiliated Brain Hospital of Guangzhou Medical University Guangzhou Huiai Hospital Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong\u2010Bin","family":"Cai","sequence":"additional","affiliation":[{"name":"Shenzhen Traditional Chinese Medicine Shenzhen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin\u2010Hu","family":"Yang","sequence":"additional","affiliation":[{"name":"The Affiliated Brain Hospital of Guangzhou Medical University Guangzhou Huiai Hospital Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Medicine Xiamen University Xiamen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor S","family":"Ungvari","sequence":"additional","affiliation":[{"name":"University of Notre Dame Australia Fremantle Western Australia Australia"},{"name":"Division of Psychiatry School of Medicine University of Western Australia Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee H","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Melbourne Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan\u2010Ming","family":"Shi","sequence":"additional","affiliation":[{"name":"Chongqing Jiangbei Mental Health Center Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei\u2010Ling","family":"Hu","sequence":"additional","affiliation":[{"name":"Shangrao Fifth People\"s Hospital Shangrao China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Ping","family":"Ning","sequence":"additional","affiliation":[{"name":"The Affiliated Brain Hospital of Guangzhou Medical University Guangzhou Huiai Hospital Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu\u2010Tao","family":"Xiang","sequence":"additional","affiliation":[{"name":"Unit of Psychiatry Faculty of Health Sciences University of Macau Macao SAR China"},{"name":"Center for Cognition and Brain Sciences University of Macau Macao SAR China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.683523"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070179"},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1291175"},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2016.06.002"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088435"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318172473c"},{"key":"e_1_2_13_9_2","first-page":"851","article-title":"Management of psychotropic\u2010induced hyperprolactinemia","volume":"11","author":"Marken PA","year":"1992","journal-title":"Clin Pharm"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0428-2"},{"key":"e_1_2_13_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117699630"},{"key":"e_1_2_13_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2016.01.031"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000607"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.1996.tb00578.x"},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199706000-00025"},{"key":"e_1_2_13_16_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.033175"},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05154yel"},{"key":"e_1_2_13_18_2","first-page":"4","article-title":"Using aripiprazole to reduce antipsychotic\u2010induced hyperprolactinemia: meta\u2010analysis of currently available randomized controlled trials","volume":"27","author":"Meng M","year":"2015","journal-title":"Shanghai Arch Psychiatry"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000579"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.2174\/1872214807666131229125700"},{"key":"e_1_2_13_21_2","first-page":"224","article-title":"Effect of aripiprazole on the hyperprolactinmia induced by risperidone in male schizophrenia patients (in Chinese)","volume":"42","author":"Chen HZ","year":"2009","journal-title":"Chinese J Psychiat"},{"key":"e_1_2_13_22_2","first-page":"145","article-title":"The treatment efficacy of olanzapine combined with aripiprazole in female first\u2010episode schizophrenia (in Chinese)","volume":"10","author":"Chen JH","year":"2012","journal-title":"Guide of China Medicine"},{"key":"e_1_2_13_23_2","article-title":"A study of aripiprazole in treatment of hyperprolactinemia induced by sulpiride (in Chinese)","volume":"24","author":"Ren LZ","year":"2011","journal-title":"Medical Information"},{"key":"e_1_2_13_24_2","first-page":"356","article-title":"Effect of low dose of aripiprazole combined with amisulpride on clinical symptoms and sexual function prolactin of male schizophrenic patients (in Chinese)","volume":"37","author":"Sha JM","year":"2017","journal-title":"Chinese Rural Health Service Administration"},{"key":"e_1_2_13_25_2","first-page":"68","article-title":"The study of aripiprazole on preventing the hyperprolactinemia induced by antipsychotics on female schizophrenic patients (in Chinese)","volume":"41","author":"Zhou P","year":"2014","journal-title":"J Int Psychiatry"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2018-000014"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2018-100007"},{"key":"e_1_2_13_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_13_29_2","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"e_1_2_13_30_2","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"e_1_2_13_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_13_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_13_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_13_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184"},{"key":"e_1_2_13_36_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-102884"},{"key":"e_1_2_13_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12631"},{"key":"e_1_2_13_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_2_13_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"e_1_2_13_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"e_1_2_13_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_13_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269216307087148"},{"key":"e_1_2_13_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(02)00304-4"},{"key":"e_1_2_13_44_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06071075"}],"container-title":["General Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1136\/gpsych-2019-100091","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1136\/gpsych-2019-100091","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1136\/gpsych-2019-100091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T10:34:41Z","timestamp":1775644481000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1136\/gpsych-2019-100091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/gpsych-2019-100091"],"URL":"https:\/\/doi.org\/10.1136\/gpsych-2019-100091","archive":["Portico"],"relation":{},"ISSN":["2096-5923","2517-729X"],"issn-type":[{"value":"2096-5923","type":"print"},{"value":"2517-729X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]},"article-number":"e100091"}}